$22.99
-0.33 (-1.42%)
Open$22.25
Previous Close$23.32
Day High$23.30
Day Low$22.25
52W High$30.67
52W Low$12.38
Volume—
Avg Volume294.3K
Market Cap74.39M
P/E Ratio45.39
EPS$0.53
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+18.7% upside
Current
$22.99
$22.99
Target
$27.28
$27.28
$18.57
$27.28 avg
$35.01
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.22M | 12.16M | 13.52M |
| Net Income | 1.67M | 1.59M | 1.78M |
| Profit Margin | 13.7% | 13.1% | 13.2% |
| EBITDA | 2.79M | 3.00M | 3.51M |
| Free Cash Flow | 1.30M | 1.27M | 1.44M |
| Rev Growth | +12.4% | +20.7% | +15.7% |
| Debt/Equity | 0.63 | 0.63 | 0.69 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |